Overview

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Status:
Not yet recruiting
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib